美沙拉嗪联合地榆七柏汤灌肠治疗活动性溃疡性结肠炎的临床研究

溃疡性结肠炎(ulcerative colitis,UC)主要累及机体结肠和直肠黏膜,属于肠黏膜的一种慢性、非特异性炎症反应,其具体发病机制不清,现研究认为UC属于在遗传易感的基础上,由肠道局部免疫功能紊乱及炎症等多种因素共同导致1-2].UC患者临床表现以下腹痛、腹泻、脓血便及里急后重等为主,美沙拉嗪是治疗UC的临...

Clinical study of Mesalazine combined with Diyuqibai Decoction enema in treatment of active ulcerative colitis

Abstract: Objective To observe the clinical efficacy and serum inflammatory factors levels in patients with acute ulcerative colitis (UC) after Mesalazine combined with Diyuqibai Decoction enema treatment. Methods A total of 84 patients with acute UC from our hospital between June 2019 to March 2020 were enrolled and randomly divided into control group and observation group (42 cases in each group). Patients in the control group were po administered with Mesalazin Enteric-coated Tablets, 1g/time, four times a day. Patients in the observation group were administered with Diyuqibai Decoction enema based on the control group, 50ml/time, once a day. All patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy, Baron scores, Mayo index, serum levels of IL-17, IL-6 and TNF-a and incidence of adverse reactions between two groups were compared. Results After 8 weeks treatment, the total effective rate in the observation and control group was 95.24% and 78.57%, respectively. When compared with the control group, the total effective rate in the observation group was significantly higher (P=0.024). After 8 weeks treatment, the Baron scores, Mayo index and serum levels of IL-17, IL-6 and TNF-a in two groups were significantly lower than those in before treatment (P<0.05). When compared with the control group, the Baron scores, Mayo index and serum levels of IL-17, IL-6 and TNF-a in observation group were significantly lower (P<0.05). The incidence of adverse reactions in two groups was 9.52% and 7.14%, respectively.There was no significant difference in the incidence of adverse reactions in two groups (P>0.05). Conclusions Diyuqibai Decoction enema can significantly improve the clinical efficacy of Mesalazine in the treatment of active UC, and can rapidly ameliorate the clinical symptoms, which may be related to the reduction of the inflammatory factors levels.